Results 121 to 130 of about 18,175 (274)

Bacterial toxins modifying the actin cytoskeleton [PDF]

, 2010
Numerous bacterial toxins recognize the actin cytoskeleton as a target. The clostridial binary toxins (Iota and C2 families) ADP-ribosylate the actin monomers causing the dissociation of the actin filaments.
Claude Bouchaud, Jean Christophe Marvaud, Jean-François Richard, Laetitia Petit, Maryse Gibert, Michel R. Popoff   +5 more
core   +2 more sources

Dorsal Genital Nerve Stimulation as an Adjunctive Therapy to Control Neurogenic Detrusor Overactivity After Spinal Cord Injury

Artificial Organs, EarlyView.
People with spinal cord injury (SCI) experience bladder overactivity, which can cause incontinence. Dorsal genital nerve stimulation (DGNS) can suppress overactivity, providing a longer duration to reach a toilet. People with SCI trialed home‐based DGNS for 8 weeks. DGNS was effective in the laboratory, and participants found home‐based DGNS acceptable.
Sean Doherty, Evangeline Martinez, Sarah Knight, Richard Nobrega, Lynsey Duffell   +4 more
wiley   +1 more source

A Targeted Therapeutic Rescues Botulinum Toxin-A Poisoned Neurons [PDF]

, 2008
Botulinum neurotoxin (BoNT), a Category A biothreat agent, is the most potent poison known to mankind. Currently no antidote is available to rescue poisoned synapses.
Bal Ram Singh, Dan Li, James Keller, Michael Adler, Peng Zhang, Prabhati Ray, Radharaman Ray   +6 more
core   +1 more source

Neurophysiological Effect of Transcutaneous Electrical Spinal Cord Stimulation in Chronic Complete Spinal Cord Injury

Artificial Organs, EarlyView.
TESCS‐ABT induced neurophysiological changes in individuals with chronic complete SCI, however these did not consistently translate into functional improvements. These findings highlight the role of residual supraspinal connectivity and inform future research to optimise this neurotechnology for SCI rehabilitation and identify likely responders ...
E. L. McNicol, B. Osuagwu, M. Purcell, E. J. McCaughey, C. Lincoln, L. Cope, A. Vučković   +6 more
wiley   +1 more source

Factors associated with flexible cystoscope longevity: an analysis of supplier and health service datasets

BJU International, EarlyView.
Objectives To investigate the associations between how reusable flexible cystoscopes (FCs) are managed during their functioning lifetime and their longevity. Patients and Methods This was an exploratory retrospective analysis of administrative data collected by a medical supplies company (KARL STORZ Endoscopy (UK) Ltd) on FC usage linked at a National ...
Joseph B. John, Robert Feasey, Ranan Dasgupta, Tim W.R. Briggs, John S. McGrath, William K. Gray   +5 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Three‐year outcomes of repeated botulinum neurotoxin A injections to the lower extremities in young children with spastic cerebral palsy in GMFCS levels I to III

Developmental Medicine &Child Neurology, EarlyView.
In this study, we followed a group of children 2 to 6 years old with spastic cerebral palsy functioning in GMFCS levels I–III, over 3 years. Sixty‐five received BoNT‐A and 59 did not. Repeated BoNT‐A injections over 3 years were not associated with improvements in gross motor function or passive ankle dorsiflexion. Daily step counts, favouring the BoNT‐
Darcy Fehlings, Emma Bohn, Lauren Switzer, Charles H. Goldsmith, Unni Narayanan, Peter L. Rosenbaum, F. Virginia Wright, Gary Foster, CP‐BoNT‐A Study Group, Timothy Carey, Mark Mason, Ronit Mesterman   +11 more
wiley   +1 more source

[Botulinum toxin Type A. Indications and results].

Revista de neurologia, 2003
Since introduction for clinical in the 80s, the botulinum toxin type A is being used with effectiveness in the treatment of different disorders that goes with exaggerated muscular activity. Numerous studies have been demonstrated useful for focal treatment of spasticity.Some indications of the botulinum toxin type A for the treatment of the cerebral ...
Póo P, López-Casas JA, Galván-Manso M, Aquino-Fariña L, Terricabras-Carol L, Campistol J   +5 more
openaire   +3 more sources

Management of an uncommon complication using botulinum toxin type A following prosthetic laryngoplasty

Equine Veterinary Education, EarlyView.
Summary An uncommon complication following prosthetic laryngoplasty was reported in a 4‐year‐old Andalusian mare. The mare was presented with a previously diagnosed left‐sided recurrent laryngeal neuropathy, after initial evaluation the mare underwent ventriculocordectomy and prosthetic laryngoplasty.
J. L. Sanclemente, D. S. Larriva, C. A. Ragle   +2 more
wiley   +1 more source

Equine botulism

Equine Veterinary Journal, EarlyView.
Abstract Botulism is a severe and often fatal disease in equine patients worldwide. Clostridium botulinum is a ubiquitous soil organism which produces a potent neurotoxin resulting in neuromuscular blockade and flaccid paralysis in affected animals. Definitive diagnosis is often impractical or impossible, leading to diagnosis and treatment based on ...
Kali Slavik, Robert Whitlock, Amy Johnson   +2 more
wiley   +1 more source